Abstract: As a core participant in human metabolism, immunity, and neural regulation, the gut microbiota has been demonstrated to be closely related to anesthesia drug metabolism and perioperative complications in recent years. Via the bidirectional interaction between the gut-brain axis and gut-liver axis, the gut microbiota and its metabolites can regulate central nervous system inflammation, liver drug-metabolizing enzyme activity, and the clearance efficiency of anesthetic drugs. Moreover, anesthetic drugs can significantly reshape the gut microbiota structure by altering intestinal barrier function, inhibiting beneficial bacterial proliferation, or inducing bile acid metabolism disorders, thereby resulting in a vicious cycle of neuroinflammation and metabolic abnormalities. Microbiota-targeted intervention strategies have demonstrated potential in alleviating anesthesia-related complications in response to this interactive network; however, their clinical translation is still limited by incomplete understanding of the underlying mechanisms, individual heterogeneity, and safety challenges. In the future, it will be necessary to integrate multiomics technologies for analyzing the tripartite interaction network of microorganisms, hosts, and drugs, as well as for promoting standardized clinical research, in order to develop individualized anesthesia management plans based on gut microbiota regulation; these initiatives can result in improvements in perioperative safety and patient prognosis.
Introduction
Anesthesia is a cornerstone of modern medicine, yet the biological response to anesthetic drugs varies significantly between individuals. Beyond simple drug-receptor interactions, clinicians face challenges like delayed drug clearance, postoperative cognitive dysfunction (POCD), and chronic postoperative pain. Traditionally, research focused on the brain as the target and the liver as the metabolic hub. However, recent evidence highlights the gut microbiota as a "hidden organ" and a core participant in metabolism and immunity, serving as the missing link in understanding perioperative outcomes.
Methodology
This review synthesizes recent advancements in metagenomics (16S rRNA sequencing) and metabolomics from both animal models and human observational studies. It specifically analyzes the signaling mechanisms of the gut-brain-liver axis, focusing on four core transmission pathways: the vagus nerve, the neuroendocrine pathway (HPA axis), immune regulatory cytokines, and microbial metabolite-mediated signaling (e.g., short-chain fatty acids [SCFAs] and bile acids).
The Gut-Brain-Liver Axis in Anesthesia
A central theme is the bidirectional interaction between the host and its microbiota. Anesthesia can impair the intestinal barrier—the "leaky gut" phenomenon—allowing lipopolysaccharides (LPS) to enter the bloodstream. This triggers a dual-path response: it suppresses liver enzymes like CYP450, slowing drug clearance, and primes neuroinflammation in the brain, which can exacerbate postoperative delirium.
Conversely, certain metabolites act as neuroprotectors. SCFAs like butyrate and tryptophan derivatives like Indole-3-propionic acid (IPA) provide protective signals. Notably, IPA levels are significantly negatively correlated with the onset of postoperative delirium, suggesting a potential biomarker or therapeutic target.
Drug-Specific Impacts on Gut Microbiota
Different anesthetic classes reshape the gut landscape in unique ways. For instance, opioids can inhibit the secretion of antimicrobial peptides and disrupt the intestinal barrier. Inhaled anesthetics like Sevoflurane may reduce the abundance of beneficial bacteria such as Akkermansia, while intravenous agents like Propofol affect different taxa, such as Prevotella and Lactobacillus.
Challenges to Clinical Translation
Despite the promising links, several hurdles remain for "precision microbial-assisted anesthesia":
- Model Discrepancies: Most mechanistic data currently comes from rodent models; human physiology and microbiota composition are significantly more complex.
- Individual Heterogeneity: Factors like diet, age, and genetics make it difficult to predict a specific patient's response to microbiome-targeted therapy.
- Standardization: There is a lack of universal protocols for interventions like Fecal Microbiota Transplantation (FMT) or specific probiotic "cocktails" in the perioperative setting.
Conclusion and Future Directions
The future of anesthesia management lies in integrating multiomics technologies to analyze the tripartite interaction network of microorganisms, hosts, and drugs. Developing a "microbiota-anesthetic drug interaction database" and utilizing machine learning to create predictive models could allow clinicians to screen a patient's microbiome before surgery, leading to truly individualized anesthesia plans and improved patient prognosis.
Summary updated